New pill combo tested for Tough-to-Treat cancers
NCT ID NCT03875287
Summary
This early-stage study is testing the safety and best dose of a new two-drug pill combination (cedazuridine with decitabine) for people with advanced solid tumors. It is for patients whose cancer has continued to grow despite at least two prior treatments and who have no other good options. The main goals are to find the highest dose patients can tolerate without severe side effects and to see how the body processes the drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90089, United States
Conditions
Explore the condition pages connected to this study.